Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad's Ovarian Cancer Test Proves Its Mettle as Tesaro Companion Dx

Executive Summary

Myriad’s myChoice HRD test has demonstrated its ability to identify more than twice as many ovarian cancer patients who may benefit from treatment with Tesaro’s drug investigational drug niraparib, compared with patient stratification by germline-BRCA testing alone.

Advertisement

Related Content

Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy
Tesaro Takes Lead: Ovarian Cancer PhIII Pushes Niraparib Ahead Of Clovis' PARP Inhibitor
Lynparza Approval Shows Benefit/Risk Contrast In Maintenance, Relapse Settings

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT103958

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel